Effect of Casodex on Tumour Hypoxia - Prostate Cancer
Prostate cancers, in common with many other tumours, are often hypoxic; that is, they have low levels of oxygen. It is thought that tumour hypoxia may hasten the progression of cancers and make them more resistant to treatment. One previous study has suggested that hormone therapy, such as Casodex, may improve the prostate oxygen level. This study is designed to test that finding.
Procedure: tumour oxygen measurements post treatment (Casodex)
|Study Design:||Allocation: Non-Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Diagnostic
|Official Title:||A Study of the Effect of Neoadjuvant Bicalutamide (Casodex) on Tumour Hypoxia in Patients With Clinically Localized Prostate Cancer|
- To determine the effect of neoadjuvant anti-androgen therapy on oxygenation of prostatic tumours, and to correlate with changes in PSA, hemoglobin level, and prostate volume.
- To enable study of the effect of neoadjuvant anti-androgen therapy on prostate tumour histopathology and gene expression, and correlation of these effects with changes in oxygenation.
|Study Start Date:||April 2001|
Please refer to this study by its ClinicalTrials.gov identifier: NCT00188708
|Princess Margaret Hospital|
|Toronto, Ontario, Canada, M5G 2M9|
|Principal Investigator:||Michael Milosevic, MD||Princess Margaret Hospital, Canada|